Safety and Efficacy Study of PI3K Delta Inhibitor in Autoimmune Hemolytic Anemia Patients Who Failed Two-round Therapy
Conditions: Autoimmune Hemolytic Anemia; Failure of Two Rounds of Treatment Intervention: Drug: Linperlisib Sponsors: Institute of Hematology & Blood Diseases Hospital; YL-Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Anemia | Autoimmune Disease | Hematology | Hospitals | Pharmaceuticals | Research | Study